top of page

Established in 2016 in Heidelberg (Germany), EXCIVA is a privately held biotech company focused on developing clinical stage therapeutics for various indications in neuropsychiatry

Our team

Board of Directors

Raphaël Wisniewski

Chairman of the Board

Raphael joined the Life Sciences Team of Andera Partners (formerly Edmond de Rothschild Investment Partners) in 2001. Previously, he worked in Healthcare Corporate Finance at Goldman Sachs, starting at Salomon Smith Barney. He is a graduate of the Ecole des Hautes Etudes Commerciales and holds a postgraduate diploma in Economics and Finance from the Institut d’Etudes Politiques (IEP), Paris. Raphaël is a Director of Axonics, Poxel, ReViral, MedDay, Grey Wolf, Enyo Pharma and Dynacure. 

Sofia Ioannidou, PhD

Board Member

Sofia joined the Life Sciences Team of Andera Partners (formerly Edmond de Rothschild Investment Partners) in 2009. Prior to this, she worked as a consultant at LEK Consulting in London and as a research scientist at Eyetech Pharmaceuticals in Boston, USA. Sofia obtained her first degree in Molecular and Cellular Biochemistry from the University of Oxford and her PhD in Cell Biology from Cancer Research UK. Sofia is a board member of LogicBio Therapeutics, Tricares, Avalyn Pharma and Sanifit. 

Harald Poth, PhD

Board Member

Harald Poth is a member of the managing board of LBBW Venture Capital, where he heads the Life Science Team, and has over 23 years of investment experience in this field. Recent successful exits under his leadership include Ganymed Pharmaceuticals GmbH, Sloning Biotechnology GmbH, Proabiogen Ag and MTM Diagnostics. Prior to his activities in venture capital, he headed the Life Science startup agency in Baden-Württemberg. He studied Biology at the University Hohenheim in Stuttgart, holds a PhD with distinction in Microbiology from Hohenheim and gained scientific experience at the Université de Genève, the University of Pennsylvania, and the Biotechnology Research Centre in Braunschweig. 

Vikram Sudarsan, PhD

Board Member

Vikram received his PhD in Neuroscience from the University of Sheffield, UK and thereafter held a post-doctoral research position at Stanford School of Medicine. Vikram is an investor and entrepreneur with over 25 years of experience in the pharma industry. His experience spans a wide spectrum of industry functions including venture capital, business development, transactions, market access and drug development. Vikram was CEO of Cipla and built a pipeline of branded products to treat disorders of the CNS. He served on the boards of Stempeutics, Chase Pharmaceuticals and Cipla. 

bottom of page